Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""PCSK9 Inhibitors"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 884
Tytuł:
Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection.
Autorzy:
Muzammil K; Department of Public Health, College of Applied Medical Sciences, King Khalid University, Khamis Mushait Campus, Abha, KSA, Saudi Arabia.
Hooshiar MH; Department of Periodontology, School of Dentistry, Terhan University of Medical Sciences, Tehran, Iran. .
Varmazyar S; Department of Medicine, Shahroud Islamic azad university of medical sciences, Sharoud, Iran.
Omar TM; Department of Medical Laboratory Technics, Al-Noor University College, Nineveh, Iraq.
Karim MM; Collage of Pharmacy, National University of Science and Technology, Dhi Qar, 64001, Iraq.
Aadi S; College of Dentistry, Al-Mustaqbal University, Babylon, 51001, Iraq.
Kalavi S; Department of Clinical Pharmacy, faculty of pharmacy, Islamic Azad University of Medical Sciences, Tehran, Iran. .
Yasamineh S; Young Researchers and Elite Club, Tabriz Branch, Islamic Azad University, Tabriz, Iran. .
Pokaż więcej
Źródło:
Microbial cell factories [Microb Cell Fact] 2024 Mar 25; Vol. 23 (1), pp. 90. Date of Electronic Publication: 2024 Mar 25.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Hepatitis C*/drug therapy
HIV Infections*/drug therapy
PCSK9 Inhibitors*/pharmacology
PCSK9 Inhibitors*/therapeutic use
Humans ; Proprotein Convertase 9/metabolism ; Subtilisins
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Application of Peptide Nucleic Acids (PNA) in the Inhibition of Proprotein Convertase Subtilisin/Kexin 9 ( PCSK9 ) Gene Expression in a Cell-Free Transcription/Translation System.
Autorzy:
Polak A; Department of Internal Medicine and Clinical Pharmacology, Faculty of Medical Science in Katowice, Medical University of Silesia, Medykow 18, 40-752 Katowice, Poland.
Machnik G; Department of Internal Medicine and Clinical Pharmacology, Faculty of Medical Science in Katowice, Medical University of Silesia, Medykow 18, 40-752 Katowice, Poland.
Bułdak Ł; Department of Internal Medicine and Clinical Pharmacology, Faculty of Medical Science in Katowice, Medical University of Silesia, Medykow 18, 40-752 Katowice, Poland.
Ruczyński J; Laboratory of Chemistry of Biologically Active Compounds, Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308 Gdańsk, Poland.
Prochera K; Laboratory of Chemistry of Biologically Active Compounds, Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308 Gdańsk, Poland.
Bujak O; Laboratory of Chemistry of Biologically Active Compounds, Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308 Gdańsk, Poland.
Mucha P; Laboratory of Chemistry of Biologically Active Compounds, Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308 Gdańsk, Poland.
Rekowski P; Laboratory of Chemistry of Biologically Active Compounds, Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308 Gdańsk, Poland.
Okopień B; Department of Internal Medicine and Clinical Pharmacology, Faculty of Medical Science in Katowice, Medical University of Silesia, Medykow 18, 40-752 Katowice, Poland.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 25; Vol. 25 (3). Date of Electronic Publication: 2024 Jan 25.
Typ publikacji:
Journal Article
MeSH Terms:
Hypercholesterolemia*/drug therapy
Hypercholesterolemia*/genetics
Peptide Nucleic Acids*/pharmacology
PCSK9 Inhibitors*/pharmacology
Humans ; Gene Expression ; Proprotein Convertase 9/drug effects ; Proprotein Convertase 9/genetics ; Proprotein Convertases/genetics ; Receptors, LDL/genetics ; Receptors, LDL/metabolism ; Subtilisin/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Predictors of functional and morphological arterial wall properties in coronary artery disease patients with increased lipoprotein (a) levels before and after treatment with proprotein convertase subtilisin-kexin type 9 inhibitors.
Autorzy:
Likozar AR; Department of Vascular Diseases, University Medical Centre Ljubljana, 1000, Ljubljana, Slovenia.
Šebeštjen M; Department of Vascular Diseases, University Medical Centre Ljubljana, 1000, Ljubljana, Slovenia. .; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. .; Department of Cardiology, University Medical Centre Ljubljana, Zaloška 7, 1000, Ljubljana, Slovenia. .
Pokaż więcej
Źródło:
Cardiovascular ultrasound [Cardiovasc Ultrasound] 2023 Aug 14; Vol. 21 (1), pp. 15. Date of Electronic Publication: 2023 Aug 14.
Typ publikacji:
Journal Article
MeSH Terms:
Coronary Artery Disease*/complications
Coronary Artery Disease*/diagnosis
Coronary Artery Disease*/drug therapy
Myocardial Infarction*
PCSK9 Inhibitors*/therapeutic use
Humans ; Carotid Intima-Media Thickness ; Lipoprotein(a) ; Proprotein Convertase 9 ; Pulse Wave Analysis ; Risk Factors ; Subtilisins ; Vascular Cell Adhesion Molecule-1
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials.
Autorzy:
Mohammadi KA; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Brackin T; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Schwartz GG; University of Colorado School of Medicine, Aurora, Colorado, USA.
Steg PG; Université Paris-Cité, Paris, France.; FACT (French Alliance for Cardiovascular Trials) INSERM U1148, Paris, France.; Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.
Szarek M; State University of New York, Downstate School of Public Health, Brooklyn, New York, USA.; CPC Clinical Research and Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Manvelian G; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Pordy R; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Fazio S; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Geba GP; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Aug; Vol. 12 (16), pp. 16859-16868. Date of Electronic Publication: 2023 Jul 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal*/therapeutic use
Neoplasms*/epidemiology
Neoplasms*/drug therapy
PCSK9 Inhibitors*/adverse effects
PCSK9 Inhibitors*/therapeutic use
Humans ; Cholesterol, LDL ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Risk Assessment ; Subtilisins ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2).
Autorzy:
Chai M; Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, No.2 Anzhen Road, ChaoYang District, Beijing, 100029, China.
He Y; Division of Cardiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Zhao W; Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
Han X; Department of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, China.
Zhao G; Department of Cardiovascular Disease, Tianjin Medical University General Hospital, Tianjin, China.
Ma X; Department of Cardiovascular Medicine, General Hospital of Ningxia Medical University, Yinchuan, China.
Qiao P; Department of Cardiology, Hainan Provincial People's Hospital, Haikou, China.
Shi D; Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, No.2 Anzhen Road, ChaoYang District, Beijing, 100029, China.
Liu Y; Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, No.2 Anzhen Road, ChaoYang District, Beijing, 100029, China.
Han W; Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, No.2 Anzhen Road, ChaoYang District, Beijing, 100029, China.
An P; Innovent Biologics, Inc., Suzhou, China.
Li H; Innovent Biologics, Inc., Suzhou, China.
Yan S; Innovent Biologics, Inc., Suzhou, China.
Ma Q; Innovent Biologics, Inc., Suzhou, China.
Deng H; Innovent Biologics, Inc., Suzhou, China.
Qian L; Innovent Biologics, Inc., Suzhou, China. .
Zhou Y; Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, No.2 Anzhen Road, ChaoYang District, Beijing, 100029, China. .
Pokaż więcej
Corporate Authors:
CREDIT-2 investigators
Źródło:
BMC medicine [BMC Med] 2023 Feb 28; Vol. 21 (1), pp. 77. Date of Electronic Publication: 2023 Feb 28.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal*/therapeutic use
Hypercholesterolemia*
Hyperlipoproteinemia Type II*/drug therapy
PCSK9 Inhibitors*/therapeutic use
Humans ; Apolipoproteins ; Cholesterol, LDL ; East Asian People ; Lipoprotein(a)
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effects of PCSK9 Inhibition on Coronary Atherosclerosis Regression of Nontarget Lesions after Primary Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients.
Autorzy:
Li Y; Department of Cardiology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, China.
Yang M; Department of Cardiology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, China.
Chen X; Department of Cardiology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, China.
Zhang R; Department of Cardiology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, China.
Li J; Department of Cardiology, Gaoyou Hospital of Traditional Chinese Medicine, Yangzhou 225600, China.
Zhang X; Department of Cardiology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, China.
Zuo P; Department of Cardiology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, China.
Ma G; Department of Cardiology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, China.
Pokaż więcej
Źródło:
Journal of interventional cardiology [J Interv Cardiol] 2022 Dec 26; Vol. 2022, pp. 4797529. Date of Electronic Publication: 2022 Dec 26 (Print Publication: 2022).
Typ publikacji:
Journal Article
MeSH Terms:
Acute Coronary Syndrome*/drug therapy
Atherosclerosis*/drug therapy
Coronary Artery Disease*/diagnostic imaging
Coronary Artery Disease*/therapy
Coronary Artery Disease*/pathology
PCSK9 Inhibitors*/pharmacology
PCSK9 Inhibitors*/therapeutic use
Humans ; Cholesterol, LDL ; Constriction, Pathologic/drug therapy ; Proprotein Convertase 9
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry.
Autorzy:
Cordero A; Cardiology Department, Hospital Universitario de San Juan, Alicante, Spain.; Unidad de Investigación en Cardiología, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
Fernández Olmo MR; Cardiology Department, Complejo Hospitalario de Jaén, Jaén, Spain.
Cortez Quiroga GA; Cardiology Department, Hospital Alto Guadalquivir, Jaén, Spain.
Romero-Menor C; Cardiology Department, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain.
Fácila L; Cardiology Department, Consorcio Hospital General de Valencia, Valencia, Spain.
Seijas-Amigo J; Cardiology Department, Complejo Hospitalario Universidad de Santiago de Compostela, Santiago de Compostela, Spain.
Rondán Murillo J; Cardiology Department, Hospital Universitario de Cabueñes, Gijón, Spain.
Sandin M; Cardiology Department, Hospital General Universitario de Alicante, Alicante, Spain.
Rodríguez-Mañero M; Cardiology Department, Complejo Hospitalario Universidad de Santiago de Compostela, Santiago de Compostela, Spain.
Bello Mora MC; Cardiology Department, Hospital de Alava, Vitoria, Spain.
Valle A; Cardiology Department, Hospital Universitario de Denia, Denia, Spain.
Fornovi A; Endocrinology Department, Hospital Vega Baja, Orihuela, Spain.
Freixa Pamias R; Cardiology Department, Hospital Sant Joan Despí Moisès Broggi, Sant Joan Despí, Barcelona, Spain.
Bañeras J; Cardiology Department, Hospital del Vall Hebrón, Barcelona, Spain.
Blanch García P; Cardiology Department, Hospital Sant Joan Despí Moisès Broggi, Sant Joan Despí, Barcelona, Spain.
Clemente Lorenzo MM; Cardiology Department, Hospital Virgen del Puerto de Plasencia, Plasencia, Spain.
Sánchez-Álvarez S; Cardiology Department, Hospital Hospital Lluis Alcanys Xátiva, Valencia, Spain.
López-Rodríguez L; Cardiology Department, Hospital Manacor, Palma de Mallorca, Spain.
González-Juanatey JR; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.; Cardiology Department, Complejo Hospitalario Universidad de Santiago de Compostela, Santiago de Compostela, Spain.
Pokaż więcej
Źródło:
European journal of clinical investigation [Eur J Clin Invest] 2022 Dec; Vol. 52 (12), pp. e13863. Date of Electronic Publication: 2022 Sep 05.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
PCSK9 Inhibitors*
Proprotein Convertase 9*
Humans ; Female ; Middle Aged ; Male ; Retrospective Studies ; Cholesterol ; Triglycerides ; Registries ; Cholesterol, HDL
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Impact of PCSK9 inhibitors in glycaemic control and new-onset diabetes.
Autorzy:
González-Lleó AM; Sección de Endocrinología y Nutrición. Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria (CHUIMI), Las Palmas de Gran Canaria, España. .; Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Universidad de Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, España. .
Sánchez-Hernández RM; Sección de Endocrinología y Nutrición. Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria (CHUIMI), Las Palmas de Gran Canaria, España.; Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Universidad de Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, España.
Plana N; Universitat Rovira i Virgili. Unidad de Medicina Vascular y Metabolismo. Unitat de Recerca Lipids i Arteriosclerosi. Hospital Universitari Sant Joan, IISPV: CIBERDEM., Reus, España.
Ibarretxe D; Universitat Rovira i Virgili. Unidad de Medicina Vascular y Metabolismo. Unitat de Recerca Lipids i Arteriosclerosi. Hospital Universitari Sant Joan, IISPV: CIBERDEM., Reus, España.
Rehues P; Universitat Rovira i Virgili. Unidad de Medicina Vascular y Metabolismo. Unitat de Recerca Lipids i Arteriosclerosi. Hospital Universitari Sant Joan, IISPV: CIBERDEM., Reus, España.
Ribalta J; Universitat Rovira i Virgili. Unidad de Medicina Vascular y Metabolismo. Unitat de Recerca Lipids i Arteriosclerosi. Hospital Universitari Sant Joan, IISPV: CIBERDEM., Reus, España.
Llop D; Universitat Rovira i Virgili. Unidad de Medicina Vascular y Metabolismo. Unitat de Recerca Lipids i Arteriosclerosi. Hospital Universitari Sant Joan, IISPV: CIBERDEM., Reus, España.
Wägner AM; Sección de Endocrinología y Nutrición. Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria (CHUIMI), Las Palmas de Gran Canaria, España.; Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Universidad de Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, España.
Masana L; Universitat Rovira i Virgili. Unidad de Medicina Vascular y Metabolismo. Unitat de Recerca Lipids i Arteriosclerosi. Hospital Universitari Sant Joan, IISPV: CIBERDEM., Reus, España.
Boronat M; Sección de Endocrinología y Nutrición. Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria (CHUIMI), Las Palmas de Gran Canaria, España.; Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Universidad de Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, España.
Pokaż więcej
Źródło:
Cardiovascular diabetology [Cardiovasc Diabetol] 2024 Jan 03; Vol. 23 (1), pp. 4. Date of Electronic Publication: 2024 Jan 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Prediabetic State*
Diabetes Mellitus*/diagnosis
Diabetes Mellitus*/drug therapy
Diabetes Mellitus*/epidemiology
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/adverse effects
Humans ; PCSK9 Inhibitors ; Proprotein Convertase 9 ; Glycemic Control ; Prospective Studies ; Glucose ; Risk Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors.
Autorzy:
Choi HD; College of Pharmacy, Yeungnam University, Gyeongbuk, Republic of Korea.
Kim JH; College of Pharmacy, Yeungnam University, Gyeongbuk, Republic of Korea.
Pokaż więcej
Źródło:
Cardiovascular therapeutics [Cardiovasc Ther] 2023 Jan 04; Vol. 2023, pp. 7362551. Date of Electronic Publication: 2023 Jan 04 (Print Publication: 2023).
Typ publikacji:
Meta-Analysis; Journal Article
MeSH Terms:
Anticholesteremic Agents*/therapeutic use
Cardiovascular Diseases*/diagnosis
Cardiovascular Diseases*/epidemiology
Cardiovascular Diseases*/prevention & control
PCSK9 Inhibitors*/therapeutic use
Humans ; Antibodies, Monoclonal/therapeutic use ; Subtilisin/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Discovery and SAR analysis of phenylbenzo[d][1,3]dioxole-based proprotein convertase subtilisin/kexin type 9 inhibitors.
Autorzy:
Li F; Department of Medicinal Chemistry, School of Pharmacy, Weifang Medical University, Weifang, China.
Zhang L; School of Stomatology, Weifang Medical University, Weifang, China.
Feng J; Shandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China.
Zhang L; Department of Medicinal Chemistry, School of Pharmacy, Weifang Medical University, Weifang, China.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 2017-2035.
Typ publikacji:
Journal Article
MeSH Terms:
Dioxoles*/pharmacology
Hepatocytes*/drug effects
Hepatocytes*/enzymology
PCSK9 Inhibitors*/pharmacology
Proprotein Convertase 9*/metabolism
Subtilisins*/antagonists & inhibitors
Subtilisins*/metabolism
Hep G2 Cells ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
Autorzy:
Imran TF; Providence VA Medical Center, Providence, Rhode Island, United States of America.; Lifespan Cardiovascular Institute, Rhode Island and Miriam Hospitals, Providence, Rhode Island, United States of America.; Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Khan AA; Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Has P; Lifespan Cardiovascular Institute, Rhode Island and Miriam Hospitals, Providence, Rhode Island, United States of America.; Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Jacobson A; Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Bogin S; Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Khalid M; Lifespan Cardiovascular Institute, Rhode Island and Miriam Hospitals, Providence, Rhode Island, United States of America.
Khan A; Northwestern University, Evanston, Illinois, United States of America.
Kim S; Weil Cornell College of Medicine, New York, New York, United States of America.
Erqou S; Providence VA Medical Center, Providence, Rhode Island, United States of America.; Lifespan Cardiovascular Institute, Rhode Island and Miriam Hospitals, Providence, Rhode Island, United States of America.; Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Choudhary G; Providence VA Medical Center, Providence, Rhode Island, United States of America.; Lifespan Cardiovascular Institute, Rhode Island and Miriam Hospitals, Providence, Rhode Island, United States of America.; Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Aspry K; Lifespan Cardiovascular Institute, Rhode Island and Miriam Hospitals, Providence, Rhode Island, United States of America.; Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Wu WC; Providence VA Medical Center, Providence, Rhode Island, United States of America.; Lifespan Cardiovascular Institute, Rhode Island and Miriam Hospitals, Providence, Rhode Island, United States of America.; Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Dec 06; Vol. 18 (12), pp. e0295359. Date of Electronic Publication: 2023 Dec 06 (Print Publication: 2023).
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Myocardial Infarction*/drug therapy
Atherosclerosis*/drug therapy
Anticholesteremic Agents*/therapeutic use
Cardiovascular Diseases*/drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use
Humans ; PCSK9 Inhibitors ; Cholesterol, LDL ; Proprotein Convertase 9/genetics ; Heart Disease Risk Factors ; RNA, Small Interfering/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk.
Autorzy:
Katzmann JL; Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Leipzig, Germany.
Becker C; Daiichi Sankyo Deutschland GmbH, München, Germany.
Bilitou A; Daiichi Sankyo Europe GmbH, München, Germany.
Laufs U; Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Leipzig, Germany.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2022 Oct 27; Vol. 17 (10), pp. e0276898. Date of Electronic Publication: 2022 Oct 27 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Anticholesteremic Agents*/pharmacology
Atherosclerosis*/prevention & control
Cardiovascular Diseases*/drug therapy
Cardiovascular Diseases*/prevention & control
Cardiovascular Diseases*/chemically induced
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use
PCSK9 Inhibitors*/therapeutic use
Humans ; Cholesterol, LDL ; Ezetimibe/therapeutic use ; Health Care Costs ; Heart Disease Risk Factors ; Risk Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Assessing the safety of lipid-modifying medications among Chinese adolescents: a drug-target Mendelian randomization study.
Autorzy:
Luo S; School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 1/F, Patrick Manson Building, 7 Sassoon Road, Hong Kong SAR, China.
Lam HS; Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.
Chan YH; Division of Cardiology, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China.
Tang CSM; Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.; Dr. Li Dak-Sum Research Centre, The University of Hong Kong, Hong Kong SAR, China.
He B; School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 1/F, Patrick Manson Building, 7 Sassoon Road, Hong Kong SAR, China.
Kwok MK; School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 1/F, Patrick Manson Building, 7 Sassoon Road, Hong Kong SAR, China.
Leung GM; School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 1/F, Patrick Manson Building, 7 Sassoon Road, Hong Kong SAR, China.
Schooling CM; School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 1/F, Patrick Manson Building, 7 Sassoon Road, Hong Kong SAR, China.; School of Public Health and Health Policy, City University of New York, New York, NY, USA.
Au Yeung SL; School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 1/F, Patrick Manson Building, 7 Sassoon Road, Hong Kong SAR, China. .
Pokaż więcej
Źródło:
BMC medicine [BMC Med] 2023 Oct 31; Vol. 21 (1), pp. 410. Date of Electronic Publication: 2023 Oct 31.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/adverse effects
Child ; Humans ; Adolescent ; Aged ; Proprotein Convertase 9 ; PCSK9 Inhibitors ; Mendelian Randomization Analysis ; East Asian People ; Cholesterol, LDL
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy.
Autorzy:
Toscano A; Internal Medicine Unit, Department of Clinical and Experimental Medicine Lipid Center, University of Messina, 98122 Messina, Italy.
Cinquegrani M; Internal Medicine Unit, Department of Clinical and Experimental Medicine Lipid Center, University of Messina, 98122 Messina, Italy.
Scuruchi M; Internal Medicine Unit, Department of Clinical and Experimental Medicine Lipid Center, University of Messina, 98122 Messina, Italy.
Di Pino A; Department of Clinical and Experimental Medicine, University of Catania, 95124 Catania, Italy.
Piro S; Department of Clinical and Experimental Medicine, University of Catania, 95124 Catania, Italy.
Ferrara V; Department of Clinical and Experimental Medicine, University of Catania, 95124 Catania, Italy.
Morace C; Internal Medicine Unit, Department of Clinical and Experimental Medicine Lipid Center, University of Messina, 98122 Messina, Italy.
Lo Gullo A; Unit of Rheumatology, Department of Medicine, ARNAS Garibaldi Hospital, 95122 Catania, Italy.
Imbalzano E; Internal Medicine Unit, Department of Clinical and Experimental Medicine Lipid Center, University of Messina, 98122 Messina, Italy.
Purrello F; Department of Clinical and Experimental Medicine, University of Catania, 95124 Catania, Italy.
Squadrito G; Internal Medicine Unit, Department of Clinical and Experimental Medicine Lipid Center, University of Messina, 98122 Messina, Italy.
Scicali R; Department of Clinical and Experimental Medicine, University of Catania, 95124 Catania, Italy.
Mandraffino G; Internal Medicine Unit, Department of Clinical and Experimental Medicine Lipid Center, University of Messina, 98122 Messina, Italy.
Pokaż więcej
Źródło:
Biomolecules [Biomolecules] 2022 Apr 09; Vol. 12 (4). Date of Electronic Publication: 2022 Apr 09.
Typ publikacji:
Journal Article
MeSH Terms:
Atherosclerosis*/drug therapy
Cardiovascular Diseases*/drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use
Hyperlipoproteinemia Type II*/drug therapy
PCSK9 Inhibitors*/therapeutic use
Proprotein Convertase 9*/blood
Humans ; Lipoproteins, LDL ; Pulse Wave Analysis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System.
Autorzy:
Ding L; Department of Pharmacy, Xiamen Cardiovascular Hospital, Xiamen University, Xiamen 361024, China.
Chen C; Department of Pharmacy, Xiamen Cardiovascular Hospital, Xiamen University, Xiamen 361024, China.
Yang Y; School of Electrical Engineering and Automation, Xiamen University of Technology, Xiamen 361024, China.
Fang J; Department of Pharmacy, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200003, China.
Cao L; Department of Cardiovascular Medicine, Xiamen Cardiovascular Hospital, Xiamen University, Xiamen 361024, China.
Liu Y; Department of Pharmacy, Xiamen Cardiovascular Hospital, Xiamen University, Xiamen 361024, China.
Pokaż więcej
Źródło:
Cardiovascular therapeutics [Cardiovasc Ther] 2022 Jan 25; Vol. 2022, pp. 9866486. Date of Electronic Publication: 2022 Jan 25 (Print Publication: 2022).
Typ publikacji:
Journal Article
MeSH Terms:
PCSK9 Inhibitors*
Proprotein Convertase 9*
Adverse Drug Reaction Reporting Systems ; Humans ; Pharmacovigilance
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study.
Autorzy:
Xu M; Department of Endocrinology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, No. 107 Yanjiang Road West, Guangzhou, 510120, China.
Zhu X; Phase I Clinical Trials Unit, The First Hospital of Jilin University, Changchun, China.
Wu J; Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Zhang Y; Department of Cardiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Zhao D; Endocrinology Center, Capital Medical University, Beijing Luhe Hospital, Beijing, China.
Wang X; Endocrinology Center, Capital Medical University, Beijing Luhe Hospital, Beijing, China.
Ding Y; Phase I Clinical Trials Unit, The First Hospital of Jilin University, Changchun, China.
Cao Y; Phase I Clinical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China.
Li C; Department of Endocrinology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Hu W; Department of Pharmacology, The Second Hospital of Anhui Medical University, Hefei, China.
Sheng J; Department of Cardiology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Luo Z; Department of Clinical Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.
Zheng Z; Department of Cardiology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Hu J; Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Liu J; Department of Endocrinology and Metabolism, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Zhou X; Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
Shen A; Department of Pharmacy, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, China.
Ding X; Department of Cardiology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, China.
Zhang Y; Department of Pharmacy, Chenzhou First People's Hospital, Chenzhou, China.
Zhao Y; Department of Emergency Medicine, Chenzhou First People's Hospital, Chenzhou, China.
Li Y; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
Zhong S; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
An S; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
Zou J; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
Yan L; Department of Endocrinology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, No. 107 Yanjiang Road West, Guangzhou, 510120, China. .
Pokaż więcej
Źródło:
BMC medicine [BMC Med] 2022 Jan 18; Vol. 20 (1), pp. 13. Date of Electronic Publication: 2022 Jan 18.
Typ publikacji:
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Hypercholesterolemia*/drug therapy
PCSK9 Inhibitors*/adverse effects
Antibodies, Monoclonal, Humanized/adverse effects ; Double-Blind Method ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Acanthaster planci Inhibits PCSK9 and Lowers Cholesterol Levels in Rats.
Autorzy:
Kamaruddin NN; Institute of Marine Biotechnology, Universiti Malaysia Terengganu, Kuala Nerus 21030, Malaysia.
Hajri NA; Institute of Marine Biotechnology, Universiti Malaysia Terengganu, Kuala Nerus 21030, Malaysia.
Andriani Y; Institute of Marine Biotechnology, Universiti Malaysia Terengganu, Kuala Nerus 21030, Malaysia.
Abdul Manan AF; Institute of Marine Biotechnology, Universiti Malaysia Terengganu, Kuala Nerus 21030, Malaysia.
Tengku Muhammad TS; Institute of Marine Biotechnology, Universiti Malaysia Terengganu, Kuala Nerus 21030, Malaysia.
Mohamad H; Institute of Marine Biotechnology, Universiti Malaysia Terengganu, Kuala Nerus 21030, Malaysia.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2021 Aug 23; Vol. 26 (16). Date of Electronic Publication: 2021 Aug 23.
Typ publikacji:
Journal Article
MeSH Terms:
PCSK9 Inhibitors*
Cholesterol/*blood
Starfish/*chemistry
Alanine Transaminase/blood ; Animals ; Aspartate Aminotransferases/blood ; Cell Death ; Cell Proliferation ; Cholesterol, LDL/blood ; Hep G2 Cells ; Humans ; Luciferases/metabolism ; Male ; Methanol ; Promoter Regions, Genetic/genetics ; Proprotein Convertase 9/genetics ; Proprotein Convertase 9/metabolism ; Rats, Sprague-Dawley ; Thymidine/pharmacology ; Triglycerides/blood ; Rats
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Finding inhibitors for PCSK9 using computational methods.
Autorzy:
Zainab R; Department of Biotechnology, Lahore College for Women University, Lahore, Pakistan.
Kaleem A; Department of Biotechnology, Lahore College for Women University, Lahore, Pakistan.
Ponczek MB; Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Abdullah R; Department of Biotechnology, Lahore College for Women University, Lahore, Pakistan.
Iqtedar M; Department of Biotechnology, Lahore College for Women University, Lahore, Pakistan.
Hoessli DC; Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Studies, University of Karachi, Karachi, Pakistan.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2021 Aug 05; Vol. 16 (8), pp. e0255523. Date of Electronic Publication: 2021 Aug 05 (Print Publication: 2021).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Drug Design*
Molecular Docking Simulation*
PCSK9 Inhibitors*
Enzyme Inhibitors/*chemistry
Enzyme Inhibitors/*isolation & purification
High-Throughput Screening Assays/*methods
Catalytic Domain ; Combinatorial Chemistry Techniques ; Humans ; Models, Molecular ; Proprotein Convertase 9/chemistry ; Protein Conformation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.
Autorzy:
Di Costanzo A; Division of Cardiology, Cardiovascular Research Center, University Magna Graecia Catanzaro, 88100 Catanzaro, Italy.
Indolfi C; Division of Cardiology, Cardiovascular Research Center, University Magna Graecia Catanzaro, 88100 Catanzaro, Italy.
Sorrentino S; Division of Cardiology, Cardiovascular Research Center, University Magna Graecia Catanzaro, 88100 Catanzaro, Italy.
Esposito G; Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples Federico II, 80134 Naples, Italy.
Spaccarotella CAM; Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples Federico II, 80134 Naples, Italy.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Jul 21; Vol. 24 (14). Date of Electronic Publication: 2023 Jul 21.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Anticholesteremic Agents*/pharmacology
Anticholesteremic Agents*/therapeutic use
Atherosclerosis*/drug therapy
Cardiovascular Diseases*/drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use
Hypertriglyceridemia*/drug therapy
Humans ; Cholesterol ; Cholesterol, LDL ; Eicosapentaenoic Acid/pharmacology ; Eicosapentaenoic Acid/therapeutic use ; Ezetimibe/pharmacology ; Ezetimibe/therapeutic use ; Fibrinolytic Agents/pharmacology ; Fibrinolytic Agents/therapeutic use ; PCSK9 Inhibitors ; Proprotein Convertase 9/metabolism ; Triglycerides
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Adjunctive therapy with lipid-lowering agents in COVID-19: a systematic review and meta-analysis of randomized controlled trials.
Autorzy:
Khalaji A; Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Behnoush AH; Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. .; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. .; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. .
Alilou S; School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Rezaee M; Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.; Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Peiman S; Department of Internal Medicine, AdventHealth Orlando Hospital, Orlando, FL, USA.
Sahebkar A; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.; Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.; School of Medicine, The University of Western Australia, Perth, Australia.; Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Pokaż więcej
Źródło:
Lipids in health and disease [Lipids Health Dis] 2023 May 08; Vol. 22 (1), pp. 61. Date of Electronic Publication: 2023 May 08.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use
Fenofibrate*
COVID-19*
Fatty Acids, Omega-3*/therapeutic use
Humans ; PCSK9 Inhibitors ; Randomized Controlled Trials as Topic ; Hypolipidemic Agents/therapeutic use ; Proprotein Convertase 9 ; Observational Studies as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 884

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies